NSRX (Nasus Pharma Ltd.) Stock Analysis - Financials

Nasus Pharma Ltd. (NSRX) is a publicly traded the market company. As of May 21, 2026, NSRX trades at $2.74 with a market cap of $32.20M and a P/E ratio of 0.00. NSRX moved +2.20% today. Year to date, NSRX is -70.05%; over the trailing twelve months it is flat. Its 52-week range spans $1.98 to $9.99. Analyst consensus is buy with an average price target of $18.00. Rallies surfaces NSRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are NSRX's key financials?

NSRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NSRX recently traded at $2.74. Market cap is $32.20M. P/E ratio is 0.00. Revenue is $0.

NSRX Key Metrics

Key financial metrics for NSRX
MetricValue
Price$2.74
Market Cap$32.20M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$9.99
52-Week Low$1.98
Volume0
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest NSRX News

Recent NSRX Insider Trades

  • Teleman Dan Benjamin bought 2.90K (~$10.90K) on Apr 22, 2026.
  • Teleman Dan Benjamin bought 15.00K (~$30.60K) on Mar 31, 2026.

NSRX Analyst Consensus

1 analysts cover NSRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.00.

Common questions about NSRX

What are NSRX's key financials?
NSRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NSRX recently traded at $2.74. Market cap is $32.20M. P/E ratio is 0.00. Revenue is $0.
Is NSRX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for NSRX. It does not provide personalized investment advice.
NSRX

NSRX